REVTORPYK™ (gedatolisib) approved by the U.S. FDA for the treatment of HR+/HER2- PIK3CA Wild-Type locally advanced or metastatic breast cancer on July 14, 2026; on track for commercial launch late third...
Barchart Research What to Expect from CELC Earnings CELC Generated August 12, 2026 Current Price $92.08 EPS Estimate $$-1.08 Consensus Rating Strong Buy Average Move 4.12% Can Celcuity Still Lose Less...
NEW YORK , Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Celcuity Inc. ("Celcuity" or the "Company") (NASDAQ: CELC). Such investors are advised to...
MINNEAPOLIS, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment...
The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Celcuity Inc. (“Celcuity” or the “Company”) (NASDAQ: CELC) investors concerning the Company’s...
LOS ANGELES , Aug. 3, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors...
Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Celcuity Inc. (“Celcuity” or “the...
RADNOR, Pa. , July 31, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ), a nationally recognized securities litigation law firm, is investigating potential violations...
NEW YORK , July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Celcuity Inc. ("Celcuity" or the "Company") (NASDAQ: CELC). Such investors are advised to...
MINNEAPOLIS, July 30, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications,...